Novel Microendoscope Ups Accuracy of Esophageal Screening

This article originally appeared here.
Share this content:
Novel Microendoscope Ups Accuracy of Esophageal Screening
Novel Microendoscope Ups Accuracy of Esophageal Screening

WEDNESDAY, July 29, 2015 (HealthDay News) -- A novel, low-cost, high-resolution microendoscope (HRME) improves the accuracy of Lugol's chromoendoscopy (LCE) for screening and surveillance of esophageal squamous cell neoplasia, according to a study published in the August issue of Gastroenterology.

Marion-Anna Protano, M.D., from Mount Sinai Medical Center in New York City, and colleagues examined the accuracy of HRME as an adjunct to LCE in 147 high-risk patients, enrolled from two U.S. and two Chinese centers.

The researchers found that for LCE versus LCE + HRME, sensitivity was 96 versus 91 percent (P = 0.0832), specificity was 48 versus 88 percent (P < 0.001), positive predictive value was 22 versus 45 percent (P < 0.0001), negative predictive value was 98 versus 98 percent (P = 0.3551), and overall accuracy was 57 versus 90 percent (P < 0.001), using a per-biopsy analysis. In per-patient analysis, the corresponding numbers were 100 versus 95 percent (P = 0.16), 29 versus 79 percent (P < 0.001), 32 versus 60 percent, 100 versus 98 percent, and 47 versus 83 percent (P < 0.001). Sixty percent of biopsies could have been spared using HRME.

"HRME may be a cost-effective optical biopsy adjunct to LCE, potentially reducing unnecessary biopsies and facilitating real-time decision making in globally underserved regions," the authors write.

One author holds a patent related to optical diagnostic technologies that has been licensed to Remicalm; another author disclosed financial ties to Gilead Pharmaceuticals.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »